Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

By afschroeder • February 17, 2026

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai TY, Revaiah PC, Dunne F, Mehran R, Budoff MJ, Kastelein JJ, Stroes ESG, Khamis R, Koenig W, Onuma Y. Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation. EuroIntervention. 2026 Feb 16;22(4):202-223. doi: 10.4244/EIJ-D-25-00598. PMID: 41697657.

Tags: Cardiology/Epi, Harbor UCLA, Publications

Myeloid cell-specific Beta2-adrenergic receptor deletion improves early cardiac injury resolution via de-repression of Anxa1

Nayak TK, Bajpai A, Patwa V, Carter RL, Enjamuri N, Gao E, Rajan S, Xiang YK, Tilley DG. Myeloid cell-specific β2-adrenergic receptor deletion improves early[...]

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle[...]

Self-powered in-stent restenosis diagnosis via magnetoelastic stents

Chen G, Kim WJ, Yang Y, Li YR, Tian J, Zhang J, Zhao X, Scott K, Defelice LG, Liu Z, Xu J, Chung T, Carol[...]